Leukemia

白血病

• 批准号: 8533073
• 负责人: A. THOMAS LOOK
• 金额: $ 5万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-05-15 至 2016-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8533073
• 关键词: Basic Science; Boston; Cancer Center; Cancer Center Support Grant; Clinical; Clinical Cancer Center; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Common Neoplasm; Communities; Complex; Cutaneous; Dana-Farber Cancer Institute; Development; Disease; Division of Clinical Sciences; Environment; Fostering; Future; Goals; Human Biology; Leadership; Malignant Neoplasms; Malignant neoplasm of prostate; Molecular; Patients; Pediatric Hospitals; Pharmacology; Phase; Plant Roots; Population; Recording of previous events; Research Support; Structure; Translational Research; base; innovation; leukemia; melanoma; oncology; programs

OVERVIEW The history of the Cancer Center's Clinical Science Division is rooted in the eariiest years of the Cancer Center. It began with the partnership of Dana-Farber Cancer Institute (DFCI) and Children's Hospital Boston (CHB), which was established in the late 1940s. The fomiation of the DF/HCC consortium has resulted in the development of a new scientific environment that fosters a high degree of inter-institutional collaboration among clinical investigators and with basic and population colleagues. It also has provided invaluable access to a far greater patient base so that promising clinical trials can be conducted in a reasonable timeframe. The result has been an enriched and cohesive scientific community unified through a commitment to translational research and supported by a single clinical tiials structure. Organization The basic organizing unit for stimulating clinical research remains the Clinical Programs. The Clinical Science Division includes ten programs that are disease-focused (e.g.. Prostate Cancer) and one that supports translational pharmacology and early phase trials (TPETT). Cutaneous Oncology and Melanoma is a new Clinical Program in this application. It has had an excellent record of translational discovery, strong multiinstitutional leadership, a favorable record of innovative trials, a renewed SPORE and active membership.

概述